Clinical trials: Postmenopausal
Postmenopausal Vulvovaginal Atrophy
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
Study if WC3011 is effective and safe in the treatment of postmenopausal vaginal dryness due to vulvovaginal atrophy.
- Trial name
- VENUS (NCT01400776)
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 70 sites in United States
- Volunteers
- 722 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT01743235
- Testing
- Testosterone, Buspirone hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Postmenopause
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
- Trial name
- NCT00543634
- Testing
- Premarin/MPA, Provera 10 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteoporosis
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
This is a Multi-Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics, Immunogenicity with Multiple…
- Trial name
- NCT04435158
- Testing
- SHR-1222
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Post-Menopausal Osteoporosis
Intra-venous Zoledronic Acid Once Yearly
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment.
- Trial name
- IVORY (NCT00984893)
- Testing
- zoledronic acid, Any oral bisphosphonates marketed in Canada
- Where
- 3 sites in Canada
- Volunteers
- 1,551 people
- Sponsor
- Novartis Pharmaceuticals
Post Menopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment.
- Trial name
- NCT02598934
- Testing
- Ibandronate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers
This study will determine the effect of acidic drugs such as proton-pump inhibitors on the pharmacokinetics of Vatalinib under fasting and fed conditions.
- Trial name
- NCT00426452
- Testing
- Vatalinib
- Volunteers
- 24 people
- Sponsor
- Novartis
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal…
- Trial name
- NCT00171704
- Testing
- Letrozole, Tamoxifen
- Where
- 13 sites in Denmark, United Kingdom
- Volunteers
- 263 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.
- Trial name
- NCT02157948
- Testing
- Denosumab (CP2), Denosumab (CP4)
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 394 people
- Sponsor
- Amgen
Postmenopause
A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women
The objective of this study is to determine the long-term safety of asoprisnil 10 mg when administered to postmenopausal women with Premarin® 0.625 mg
- Trial name
- NCT00152295
- Testing
- Asoprisnil/Premarin
- Volunteers
- 18 people
- Sponsor
- Abbott
Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
The purpose of this study is to assess to what extent sequential treatment with odanacatib results in incremental gains in bone mineral density (BMD) over time in female participants who have received at least 3 years of…
- Trial name
- NCT01803607
- Testing
- odanacatib
- Volunteers
- 135 people
- Sponsor
- Merck Sharp & Dohme LLC
Female Urogenital Diseases, Urinary Incontinence
Clinical Trial of "Magic Gyno" Laser Device
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose.
- Conditions
- Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital, Menopausal Syndrome
- Trial name
- NCT05463081
- Testing
- Laser treatment, Blood test, Clinical urine test
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- MeLSyTech, Ltd
Quality of Life
ATAC - Quality of Life Sub-Protocol
To compare Quality of Life between the ARIMIDEX group, the NOLVADEX group and the ARIMIDEX plus NOLVADEX combination group during the first two years of treatment.
- Trial name
- NCT00784680
- Testing
- Anastrozole, Tamoxifen
- Volunteers
- 308 people
- Sponsor
- AstraZeneca
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Progression-free Survival
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who…
- Trial name
- NCT00944918
- Testing
- fulvestrant, anastrozole, exemestane
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Hormone Replacement Therapy
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
Multicenter, double-blind, controlled, parallel group, randomized study to compare the clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine estrogen tablets, each administered orally, once daily…
- Trial name
- NCT01070979
- Testing
- Estradiol acetate, Estradiol, Conjugated equine estrogens
- Where
- 32 sites in United States
- Volunteers
- 249 people
- Sponsor
- Warner Chilcott
Osteoporosis, Postmenopausal
A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
The purpose of this study is to see how well alendronate and calcium as compared to calcium alone increase bone density in postmenopausal women with osteoporosis
- Trial name
- NCT00398606
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 2 Years, Comparator : calcium carbonate /Duration of Treatment : 2 Years
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with…
- Trial name
- PEAK (NCT00365456)
- Testing
- Parathyroid Hormone (PTH), Risedronate
- Where
- Denmark
- Volunteers
- 407 people
- Sponsor
- Takeda
Osteopenia
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
- Trial name
- NCT00902356
- Testing
- AMG 167
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Amgen